Viracta Therapeutics, Inc. (VIRX) is a publicly traded company in the Unknown sector. Across all available filings, 5 corporate insiders have executed 71 transactions totaling $496.4K, demonstrating a bearish sentiment with -$309.5K in net insider flow. The most recent transaction on Aug 25, 2024 involved a transaction of 9,034 shares valued at $0.
No significant insider buying has been recorded for VIRX in the recent period.
No significant insider selling has been recorded for VIRX in the recent period.
Based on recent SEC filings, insider sentiment for VIRX is bearish with an Insider Alignment Score of 19/100 and a net flow of -$309.5K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Viracta Therapeutics, Inc. (VIRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 5 insiders are actively trading VIRX stock, having executed 71 transactions in the past 90 days. The most active insider is Ivor Royston (Executive), who has made 16 transactions totaling $170.1K.
Get notified when executives and directors at VIRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 25, 2024 | Pomerantz Roger | Executive | Option Exercise | 9,034 | $N/A | $0 | |
| Aug 25, 2024 | Royston Ivor | Executive | Option Exercise | 25,219 | $N/A | $0 | |
| May 25, 2024 | Royston Ivor | Executive | Option Exercise | 25,219 | $N/A | $0 | |
| May 25, 2024 | Pomerantz Roger | Executive | Option Exercise | 9,035 | $N/A | $0 | |
| Feb 27, 2024 | R. Chevallard Daniel | Executive | Sale | 3,405 | $0.73 | $2.5K | |
| Feb 25, 2024 | R. Chevallard Daniel | Executive | Option Exercise | 6,889 | $N/A | $0 | |
| Feb 25, 2024 | Pomerantz Roger | Executive | Option Exercise | 9,034 | $N/A | $0 | |
| Feb 25, 2024 | Royston Ivor | Executive | Option Exercise | 25,219 | $N/A | $0 | |
| Dec 1, 2023 | Rothera Mark | Executive | Purchase | 47,906 | $0.49 | $23.5K | |
| Nov 30, 2023 | Rothera Mark | Executive | Purchase | 52,094 | $0.49 | $25.5K | |
| Nov 28, 2023 | R. Chevallard Daniel | Executive | Sale | 3,720 | $0.50 | $1.9K | |
| Nov 25, 2023 | Pomerantz Roger | Executive | Option Exercise | 9,034 | $N/A | $0 | |
| Nov 25, 2023 | Royston Ivor | Executive | Option Exercise | 25,219 | $N/A | $0 | |
| Nov 25, 2023 | R. Chevallard Daniel | Executive | Option Exercise | 6,889 | $N/A | $0 | |
| Aug 28, 2023 | R. Chevallard Daniel | Executive | Sale | 3,512 | $1.45 | $5.1K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 23 | $403.0K | 70.6% |
Purchase(P) | 3 | $93.5K | 16.4% |
Exercise(M) | 45 | $74.7K | 13.1% |
Insider selling pressure at Viracta Therapeutics, Inc. has increased, with 5 insiders executing 71 transactions across all time. Total sales of $403.0K significantly outpace purchases of $93.5K, resulting in a net outflow of $309.5K. This selling activity appears largely discretionary, which may warrant closer attention from investors.